Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis
- PMID: 31917844
- PMCID: PMC6960475
- DOI: 10.1182/bloodadvances.2019000561
Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis
Abstract
An improved understanding of which patients are at higher risk of recurrent venous thromboembolism (VTE) is important to designing interventions to reduce degraded quality of life after VTE. Although metabolic syndrome (MetS), the clustering of hypertension, hyperlipidemia, diabetes mellitus, and obesity has been associated with a hypofibrinolytic state, data linking VTE recurrence with MetS remain limited. The purpose of this study was to measure the prevalence of MetS in patients with deep vein thrombosis (DVT) across a large population and determine its effect on VTE recurrence. This was a retrospective analysis of a large statewide database from 2004 to 2017. We measured the frequency with which patients with DVT carried a comorbid International Coding of Diseases diagnosis of MetS components. Association of MetS with VTE recurrence was tested with a multiple logistic regression model and VTE recurrence as the dependent variable. Risk of VTE recurrence conferred by each MetS component was assessed by Kaplan-Meier curves with the log-rank statistic. A total of 151 054 patients with DVT were included in this analysis. Recurrence of VTE occurred in 17% overall and increased stepwise with each criterion for MetS. All 4 components of MetS had significant adjusted odds ratios (OR) for VTE recurrence, with hyperlipidemia having the largest (OR, 1.8), representing the 4 largest ORs of all possible explanatory variables. All 4 MetS variables were significant on Kaplan-Meier analysis for recurrence of VTE. These data imply a role for appropriate therapies to reduce the effects of MetS as a way to reduce risk of VTE recurrence.
© 2020 by The American Society of Hematology.
Conflict of interest statement
Conflict-of-interest disclosure: Indiana University has received funding from Janssen and Pfizer pharmaceuticals for investigator-initiated research by J.A.K. L.K.S. declares no competing financial interests.
Figures
Similar articles
-
Metabolic Syndrome Increases Risk of Venous Thromboembolism Recurrence after Acute Pulmonary Embolism.Ann Am Thorac Soc. 2020 Jul;17(7):821-828. doi: 10.1513/AnnalsATS.201907-518OC. Ann Am Thorac Soc. 2020. PMID: 32187500 Free PMC article.
-
Association between metabolic syndrome and venous thromboembolism after total joint arthroplasty: a meta-analysis of cohort studies.J Orthop Surg Res. 2020 Nov 30;15(1):570. doi: 10.1186/s13018-020-02097-4. J Orthop Surg Res. 2020. PMID: 33256765 Free PMC article.
-
Symptomatic perioperative venous thromboembolism is a frequent complication in patients with a history of deep vein thrombosis.J Vasc Surg. 2010 Sep;52(3):651-7. doi: 10.1016/j.jvs.2010.04.029. Epub 2010 Jun 16. J Vasc Surg. 2010. PMID: 20558025
-
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?Blood Adv. 2020 Nov 10;4(21):5595-5606. doi: 10.1182/bloodadvances.2020002268. Blood Adv. 2020. PMID: 33170937 Free PMC article. Review.
-
Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.Cochrane Database Syst Rev. 2017 Aug 23;8(8):CD010837. doi: 10.1002/14651858.CD010837.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2018 Nov 08;11:CD010837. doi: 10.1002/14651858.CD010837.pub4. PMID: 28832905 Free PMC article. Updated. Review.
Cited by
-
Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems.Molecules. 2024 Oct 15;29(20):4883. doi: 10.3390/molecules29204883. Molecules. 2024. PMID: 39459251 Free PMC article. Review.
-
While the Incidence of Venous Thromboembolism After Shoulder Arthroscopy Is Low, the Risk Factors Are a Body Mass Index Greater than 30 and Hypertension.Arthrosc Sports Med Rehabil. 2023 Dec 6;6(1):100815. doi: 10.1016/j.asmr.2023.100815. eCollection 2024 Feb. Arthrosc Sports Med Rehabil. 2023. PMID: 38149088 Free PMC article.
-
Platelet mitochondria: the mighty few.Curr Opin Hematol. 2023 Sep 1;30(5):167-174. doi: 10.1097/MOH.0000000000000772. Epub 2023 Jul 17. Curr Opin Hematol. 2023. PMID: 37459354 Free PMC article. Review.
-
Protein Markers of Diabetes Discovered in an African American Cohort.Diabetes. 2023 Apr 1;72(4):532-543. doi: 10.2337/db22-0710. Diabetes. 2023. PMID: 36630488 Free PMC article.
-
Genetic Predisposition of Both Waist Circumference and Hip Circumference Increased the Risk of Venous Thromboembolism.Thromb Haemost. 2023 Mar;123(3):347-361. doi: 10.1055/a-1980-8852. Epub 2022 Nov 16. Thromb Haemost. 2023. PMID: 36384228 Free PMC article.
References
-
- Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25(3):235-242. - PubMed
-
- Cushman M, Tsai AW, White RH, et al. . Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25. - PubMed
-
- Park B, Messina L, Dargon P, Huang W, Ciocca R, Anderson FA. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. Chest. 2009;136(4):983-990. - PubMed
-
- White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4-I8. - PubMed
-
- Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578-589. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
